Chinese Journal of Integrative Medicine

, Volume 22, Issue 9, pp 653–659 | Cite as

Long-term clinical effect of Tangyiping Granules (糖异平颗粒) on patients with impaired glucose tolerance

  • Yan-qin Huang (黄延芹)
  • Qing-feng Yang (杨清峰)
  • Hua Wang (王 华)
  • Yun-sheng Xu (徐云生)Email author
  • Wei Peng (彭 伟)
  • Yue-hua Jiang (姜月华)
Original Article



To evaluate the long-term clinical effect of Tangyiping Granules (糖异平颗粒, TYP) on patients with impaired glucose tolerance (IGT) to achieve normal glucose tolerance (NGT) and hence preventing them from conversion to diabetes mellitus (DM).


In total, 127 participants with IGT were randomly assigned to the control (63 cases, 3 lost to follow-up) and treatment groups (64 cases, 4 lost to follow-up) according to the random number table. The control group received lifestyle intervention alone, while the patients in the treatment group took orally 10 g of TYP twice daily in addition to lifestyle intervention for 12 weeks. The rates of patients achieving NGT or experiencing conversion to DM as main outcome measure were observed at 3, 12, and 24 months after TYP treatment. The secondary outcome measures included fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2hPG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), 2-h insulin (2hINS), homeostatic model assessment of insulin resistance (HOMA-IR), blood lipid and patients' complains of Chinese medicine (CM) symptoms before and after treatment.


A higher proportion of the treatment group achieved NGT compared with the control group after 3-, 12- and 24-month follow-up (75.00% vs. 43.33%, 58.33% vs. 35.00%, 46.67% vs. 26.67%, respectively, P<0.05). The IGT to DM conversion rate of the treatment group was significantly lower than that of the control group at the end of 24-month follow-up (16.67% vs. 31.67%, P<0.05). Before treatment, FPG, 2hPG, HbA1c, FINS, 2hINS, HOMA-IR, triglyceride (TG), total cholesterol, low- and high-density lipoprotein cholesterol levels had no statistical difference between the two groups (P>0.05). After treatment, the 2hPG, HbA1c, HOMA-IR, and TG levels of the treatment group decreased significantly compared with those of the control group (P<0.05). CM symptoms such as exhaustion, irritability, chest tightness and breathless, spontaneous sweating, constipation, and dark thick and greasy tongue were significantly improved in the treatment group as compared with the control group (P<0.05). No severe adverse events occurred.


TYP administered at the IGT stage with a disciplined lifestyle delayed IGT developing into type 2 DM.


Tangyiping Granules conversion of impaired glucose tolerance long-term clinical effect Chinese medicine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64–S71.CrossRefGoogle Scholar
  2. 2.
    Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–959.CrossRefPubMedGoogle Scholar
  3. 3.
    Xiang HD, Wu W, Liu CQ, Li K, Feng JG, Zhang YT, et al. The 1996 national diabetes epidemiological features of the baseline survey report. Chin Diabetes (Chin) 1998;6:131–133.Google Scholar
  4. 4.
    Mainous AG 3rd, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open 2014;4:e005002.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rosettenstein K, Viecelli A, Yong K, Nguyen HD, Chakera A, Chan D, et al. Diagnostic accuracies of glycated hemoglobin, fructosamine, and homeostasis model assessment of insulin resistance in predicting impaired fasting glucose, impaired glucose tolerance, or new onset diabetes after transplantation. Transplantation 2015: 292:657–658.Google Scholar
  6. 6.
    Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. New Engl J Med 2010;362:1090–1101.CrossRefPubMedGoogle Scholar
  8. 8.
    Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.CrossRefGoogle Scholar
  9. 9.
    Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med 2013;159:543–551.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanaya AM, Narayan KM. Prevention of type 2 diabetes: data from recent trials. Prim Care 2003;30:511–526.CrossRefPubMedGoogle Scholar
  11. 11.
    Laakso M. Prevention of type 2 diabetes. Curr Molecul Med 2005;5:365–374.CrossRefGoogle Scholar
  12. 12.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393–403.CrossRefPubMedGoogle Scholar
  13. 13.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077.CrossRefPubMedGoogle Scholar
  14. 14.
    Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immun Disord Drug Targets 2008;8:99–111.CrossRefGoogle Scholar
  15. 15.
    Xu YS, Huang YQ. Clinical observation of Tangyiping Water Pills in treatment of patients with impaired glucose tolerance and the effect on glucolipid metabolism and inflammatory factors. Chin J Inf Tradit Chin Med (Chin) 2012;19:13–15.Google Scholar
  16. 16.
    Trumbo P, Schlincker S, Yates AA, Poos M, Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. J Am Diet Assoc 2002;102:1621–1630.CrossRefPubMedGoogle Scholar
  17. 17.
    Zheng XY, ed. Guiding principle of clinical research on new Chinese medicine drugs. Beijing: China Medical Science and Technology Press;2002:233–237.Google Scholar
  18. 18.
    Ishikawa S, Shimano M, Watarai M, Koyasu M, Uchikawa T, Ishii H, et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol 2014;114:384–388.CrossRefPubMedGoogle Scholar
  19. 19.
    Ring M, Eriksson MJ, Fritz T, Nyberg G, Östenson CG, Krook A, et al. Influence of physical activity and gender on arterial function in type 2 diabetes, normal and impaired glucose tolerance. Diab Vasc Dis Res 2015;12:315–324.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zhao Y, Li X, Tang S. Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early type 2 diabetes mellitus. Diabetes Res Clin Pract 2015;109:372–377.CrossRefPubMedGoogle Scholar
  21. 21.
    Sinnott M, Kinsley BT, Jackson AD, Walsh C, O'Grady T, Nolan JJ, et al. Fasting plasma glucose as initial screening for diabetes and prediabetes in irish adults: The Diabetes Mellitus and Vascular Health Initiative (DMVhi). PLoS One 2015;15;10:e0122704.CrossRefGoogle Scholar
  22. 22.
    Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu C. TRIPOD Research Introduction and review of Liaoning. J Pract Diabetol (Chin) 2004;12:7–9.Google Scholar
  24. 24.
    Fang J, Wei H, Sun Y, Zhang X, Liu W, Chang Q, et al. Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen Capsule). BMC Complement Alternat Med 2013;13:280–282.CrossRefGoogle Scholar
  25. 25.
    Fang Z, Zhao J, Shi G, Shu Y, Ni Y, Wang H, et al. Shenzhu Tiaopi Granule combined with lifestyle intervention therapy for impaired glucose tolerance: a randomized controlled trial. Complement Therap Med 2014;22:842–850.CrossRefGoogle Scholar
  26. 26.
    Liu M, Qin J, Hao Y, Liu M, Luo J, Luo T, et al. Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: involvement of ROSERK and NF-kappaB pathways. Oxid Med Cell Longev 2013;2013:782497.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Jiang S, Wang Y, Ren D, Li J, Yuan G, An L, et al. Antidiabetic mechanism of Coptis chinensis polysaccharide through its antioxidant property involving the JNK pathway. Pharm Biol 2015;53:1022–1029.CrossRefPubMedGoogle Scholar
  28. 28.
    Kianbakht S, Dabaghian FH. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo controlled clinical trial. Complement Ther Med 2013;21:441–446.CrossRefPubMedGoogle Scholar
  29. 29.
    She S, Liu W, Li T, Hong Y. Effects of puerarin in STZinduced diabetic rats by oxidative stress and the TGFbeta1/Smad2 pathway. Food Funct 2014;5:944–950.CrossRefPubMedGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Yan-qin Huang (黄延芹)
    • 1
  • Qing-feng Yang (杨清峰)
    • 1
  • Hua Wang (王 华)
    • 1
  • Yun-sheng Xu (徐云生)
    • 2
    Email author
  • Wei Peng (彭 伟)
    • 1
  • Yue-hua Jiang (姜月华)
    • 1
  1. 1.Department of EndocrinologyAffiliated Hospital of Shandong University of Traditional Chinese MedicineJinanChina
  2. 2.Department of EndocrinologyThe Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineJinanChina

Personalised recommendations